Clinical Trials Browser

Phase 2 × Adenocarcinoma, Clear Cell × Gynecologic × Clear all

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT05460000 2026-02-12

N-Plus

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT05032040 2025-02-07

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Phase 2 Active not recruiting

GenitourinaryGynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT03241745 2024-12-27

A Study of Nivolumab in Selected Uterine Cancer Patients

Phase 2 Completed

35 enrolled 8 charts

GynecologicSarcoma

Carcinosarcoma, Leiomyosarcoma, Uterine Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Phase 2 Completed

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT00231829 2012-04-24

A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

Phase 2 Terminated

Uterine Neoplasms, Adenocarcinoma, Clear Cell